Gapping up
In reaction to earnings/guidance:
- BPTS +5%
Other news:
- ABCL +10.3% (FDA expands EUA for bamlanivimab 700 mg and etesevimab 1400 mg to include post-exposure prophylaxis to prevent SARS-CoV-2 infection or symptomatic COVID-19)
- AGEN +6.3% (Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in Data to Be Presented at ESMO)
- FANG +5.4% (approves up to $2.0 bln in new repurchase program)
- VBLT +4.6% (announces independent data safety monitoring committee provides clearance to continue the OVAL phase 3 registration-enabling study of VB-111 in Ovarian Cancer)
- ZUMZ +3.4% (approves $150 mln stock repurchase authorization)
- CLNN +2.9% (Presents Phase 2 CNM-Au8 CNS Target Engagement Data at the International Parkinson and Movement Disorder Society Virtual Congress 2021)
- GRTS +2.7% (announces $55 mln private placement financing)
- CVGW +1.4% (interim CEO/interim CFO purchased 5000 shares at $36.12 per share (transaction date 9/14))
- PCG +1.1% (filed an application with the California Public Utilities Commission requesting cost recovery of ~$1.47 bln of recorded expenditures related to wildfire mitigation certain catastrophic events and a number of other activities)
- GLPG +1.1% (confirms that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for Jyseleca)
- GLT +1% (will increase prices for all composite fibers products by 12%)
Analyst comments:
- HSBC +1.7% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- ACCD +1.2% (upgraded to Outperform from Neutral at Robert W. Baird)